... - the SR1 receptor will solve all these indications or none of them.
I have to disagree with that analysis. There are multiple trails going on for different indications. There is no reason to assume an all or nothing dichotomy. 2-73 can work moderately in one indication and better in another. Each of these indications has a different cause with different biochemical pathways involved as well as a lot of common pathways.
2-73 appears to improve the common pathways. So far the data suggest that is enough to have a positive impact on each of the indications being tested. So far there is no magic bullet. There is evidence of improvement. In several cases it appears to be improvement where there are no available treatments. That is more than good enough for 2-73 to get approved for one or more indications.
The situation is binary only in the sense that the drug will be approved or it will not. What is missing in that analysis is that 2-73 has multiple opportunities at that binary situation thus it is not a 50/50 situation as your analysis implies.
The amazing results have already come out with P2A AD, PDD, RTT clinical results of testing A-273 on humans. NOTHING NEGATIVE. ALL PROOF OF MOA. No one has produced a shred of negative evidence in the 12 years of testing A-273!
AVXL and A-273 is clearly a winner. The remainder of trials will be repeat performances of positivity. Let’s get this out curing sick people NOW.
Market Data 
Markets 
AI
